Icovamenib

From WikiMD.com Medical Encyclopedia

A small molecule inhibitor targeting mutant IDH1


{{Drugbox | verifiedfields = changed | verifiedrevid = 477002548 | IUPAC_name = (2S)-2-[[4-(2-chlorophenyl)-5-(4-methoxyphenyl)-1H-imidazol-2-yl]methylamino]butanamide | image = BMF-219.svg | image_size = 250px | image_alt = Chemical structure of Icovamenib }}

Icovamenib is a small molecule inhibitor that specifically targets the mutant form of the enzyme isocitrate dehydrogenase 1 (IDH1). It is being investigated for its potential use in the treatment of certain types of cancer, particularly those characterized by the presence of the IDH1 mutation.

Mechanism of Action[edit | edit source]

Icovamenib functions by inhibiting the mutant IDH1 enzyme. The IDH1 mutation leads to the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which contributes to the development and progression of cancer by altering cellular metabolism and epigenetic regulation. By inhibiting the mutant IDH1, icovamenib reduces the levels of 2-HG, thereby potentially reversing the oncogenic effects and restoring normal cellular function.

Clinical Development[edit | edit source]

Icovamenib is currently undergoing clinical trials to evaluate its efficacy and safety in patients with cancers harboring the IDH1 mutation. These trials are crucial for determining the appropriate dosing, potential side effects, and overall therapeutic benefit of the drug.

Potential Indications[edit | edit source]

The primary focus of icovamenib's development is for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma, both of which can be associated with IDH1 mutations. The presence of these mutations in a subset of patients makes them potential candidates for targeted therapy with icovamenib.

Pharmacokinetics[edit | edit source]

The pharmacokinetic profile of icovamenib is being studied to understand its absorption, distribution, metabolism, and excretion (ADME) properties. This information is essential for optimizing dosing regimens and ensuring maximum efficacy with minimal toxicity.

Safety and Tolerability[edit | edit source]

As with any investigational drug, the safety and tolerability of icovamenib are being closely monitored in clinical trials. Common adverse effects, dose-limiting toxicities, and any serious adverse events are documented to ensure patient safety and guide future use.

Related pages[edit | edit source]

WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD